Patents Assigned to Boston Biomedical, Inc.
  • Patent number: 8299106
    Abstract: The present invention relates to novel thiazole-substituted indolin-2-ones as inhibitors of CSCPK and related kinases; to methods of inhibiting cancer stem cells by using a kinase inhibitor; to pharmaceutical compositions containing such compounds; and to methods of using such compounds in the treatment of a protein kinase related disorder in a mammal; and to processes of making such compounds and intermediates thereof.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: October 30, 2012
    Assignee: Boston Biomedical, Inc.
    Inventors: Chiang Jia Li, Ji-Feng Liu, Youzhi Li, Wei Li, Harry Rogoff
  • Publication number: 20120252763
    Abstract: The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof, and to the pharmaceutical composition of relevant compounds, and to the specific methods of administration of these compounds.
    Type: Application
    Filed: September 10, 2008
    Publication date: October 4, 2012
    Applicant: Boston Biomedical, Inc.
    Inventors: Chiang Jia Li, Zhiwei Jiang, Harry Rogoff, Youzhi Li, Jifeng Liu, Wei Li
  • Publication number: 20110112180
    Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: September 10, 2008
    Publication date: May 12, 2011
    Applicant: Boston Biomedical, Inc.
    Inventors: Zhiwei Jiang, Chiang Jia Li, Wei Li, David Leggett
  • Publication number: 20100286378
    Abstract: The present invention provides double-stranded RNA molecules that are asymmetrical in strand length. The RNA molecule of the invention, the asymmetric RNA duplex, has one or two overhangs at the end. In one aspect, these novel RNA duplex molecules serve as effective mimetics of miRNA. In another aspect, they are designed to function as effective inhibitors of miRNA. Accordingly, the RNA molecules of the present invention can be used to modulate miRNA pathway activities, with tremendous implications for research, drug discovery and development, and treatment of human diseases.
    Type: Application
    Filed: August 27, 2008
    Publication date: November 11, 2010
    Applicant: Boston Biomedical, Inc.
    Inventors: Chiang Jia Li, Harry Rogoff